Search

MEPs adopted their proposals to renew EU pharmaceutical legislation, promote innovation, and enhance the security of supply, accessibility, and affordability of medicines.

During last January, Merck, IBM and the University of Navara-Tecnun presented a new edition of 'Smarth Health Awareness', the training program aimed for healthcare professionals and managers on AI and

Ysios Capital participates in the financing round for the capital increase of the US company Engrail Therapeutics.

Subhendu Basu replaces Roberto Diez-Martinez in the position, who becomes Chief Operating Officer.

AseBio, from March 20 to 22, will participate in Transfiere, the largest European event on R&D&I and knowledge transfer European Forum for Science, Technology and Innovation.

The Spanish biotech industry is present throughout the value chain of advanced therapy development and manufacturing, with 47 entities working in this field. Over 30 biotechnology companies have

On the occasion of World Kidney Day, we interviewed Isabel Portero, founder and CEO of Biophope, a biotechnology company focused on precision medicine in the areas of immunosuppression and autoimmune

The future Deep Tech Strategy takes up the challenge of the proposal for the creation of a High Commissioner for Deep Strategic Technologies made jointly by the four entities.

The combination creates a global company that offers the most comprehensive digestive health portfolio available today.

AbilityPharma closes €7 million round to fully fund its international Phase 2b clinical trial with the antitumor drug ABTL0812 in pancreatic cancer patients.

The benchmark event for investors and biotechnology companies will host a panel discussion focused on the challenge of investing in start-ups and companies active in the bioeconomy sector in Spain.

On the occasion of International Women's Day, AseBio organized the first session "Biotech women for a better science and innovation", a meeting that brought together students and professionals from

We organize the event "Women in Biotech for Better Science and Innovation," highlighting the significant role of women in the biotechnology industry.

How can Life Sciences companies ensure that the solutions they spend years developing truly respond to patient needs?

Meet our team at the 2024 Society of Toxicology (SOT) Annual Meeting and ToxExpo We will also attend BioEurope Spring 2024, the partnering event for biotech and pharma companies!

2024 Smart Agrifood Summit; TRANSFIERE 2024, 3rd European Meeting on Science, Technology and Innovation!

The project will be undertaken by a public-private consortium formed by VIVEbiotech, Integra Therapeutics and OneChain Immunotherapeutics, the UPF, the IBMB-CSIC and the CIEMAT over the next four

A consortium led by the Spanish company OneChain Immunotherapeutics has received 1.9M euros from the Spanish Ministry of Science and Innovation to advance a groundbreaking therapy, based on CAR T

Biotechnology is providing answers to rare diseases in areas with unresolved clinical needs such as diagnosis and treatment, through advanced therapies, biomarkers, and the development of new

OneChain Immunotherapeutics (OCI), a clinical-stage biotechnology company focused on the development of CAR T therapies for the treatment of oncologic diseases, announced Stefanos Theoharis as the

ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic.